| dbo:abstract |
Givinostat ist ein in der klinischen Entwicklung befindlicher potenzieller Arzneistoff, der zur Behandlung der systemischen juvenilen idiopathischen Arthritis und der Polyzythämie eingesetzt werden soll. Arzneilich wird es als Hydrochlorid verwendet und befindet sich im Moment in Phase-2-Studien. (de) Givinostat (INN) or gavinostat (originally ITF2357) is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. It is a hydroxamate used in the form of its hydrochloride. Givinostat is in numerous phase II clinical trials (including for relapsed leukemias and myelomas), and has been granted orphan drug designation in the European Union for the treatment of systemic juvenile idiopathic arthritis, polycythaemia vera. and Duchenne muscular dystrophy. A preclinical study produced early results suggesting the molecule might help with diastolic dysfunction. ITF2357 was discovered at Italfarmaco of Milan, Italy. It was patented in 1997 and first described in the scientific literature in 2005. (en) Givinostat ou gavinostat é um potêncial fármaco com propriedades anti-inflamatórias, antineoplásicas e antiangiogênese. Pertence a classe dos inibidores de HDAC (histone deacetylase). (pt) |
| dbo:casNumber |
497833-27-9 |
| dbo:fdaUniiCode |
5P60F84FBH |
| dbo:pubchem |
9804992 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Givinostat_structure.svg?width=300 |
| dbo:wikiPageExternalLink |
http://www.orpha.net/consor/cgi-bin/OC_Exp.php%3Flng=EN&Expert=85414%7Cat=Orphan |
| dbo:wikiPageID |
28807921 (xsd:integer) |
| dbo:wikiPageLength |
8655 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1033026498 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Pathophysiology dbr:Anti-inflammatory dbr:Hodgkin's_lymphoma dbr:Cytokine dbr:Interleukin_6 dbr:Leukopenia dbc:Experimental_drugs dbr:Orphan_drug dbr:Antineoplastic dbr:Platelet dbr:Janus_kinase_2 dbr:Fatigue_(medical) dbr:Juvenile_idiopathic_arthritis dbc:Histone_deacetylase_inhibitors dbc:Orphan_drugs dbr:Duchenne_muscular_dystrophy dbr:European_Union dbr:Diarrhea dbr:Histone_deacetylase_inhibitor dbr:QT_interval dbc:Diethylamino_compounds dbr:Histone_deacetylase dbr:International_Nonproprietary_Name dbr:Hydrochloride dbc:Hydroxamic_acids dbr:Adverse_drug_reaction dbr:Salvage_therapy dbr:White_blood_cell dbr:Thrombocytopenia dbr:Myeloproliferative_disease dbr:Tumour_necrosis_factor dbr:Hydroxamate dbr:Polycythaemia_vera dbr:Erythrocyte dbr:Interleukin_1 dbr:Anti-angiogenic |
| dbp:atcPrefix |
none (en) |
| dbp:c |
24 (xsd:integer) |
| dbp:casNumber |
497833 (xsd:integer) |
| dbp:chemspiderid |
7980752 (xsd:integer) |
| dbp:h |
27 (xsd:integer) |
| dbp:iupacName |
{6-[methyl]naphthalen-2-yl}methyl [4-phenyl]carbamate (en) |
| dbp:iupharLigand |
7490 (xsd:integer) |
| dbp:legalEuComment |
Orphan status for sJIA (en) |
| dbp:legalUs |
IND (en) |
| dbp:n |
3 (xsd:integer) |
| dbp:o |
4 (xsd:integer) |
| dbp:pregnancyCategory |
— (en) |
| dbp:pubchem |
9804992 (xsd:integer) |
| dbp:routesOfAdministration |
Oral (en) |
| dbp:smiles |
O=CNc3cccCNO (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
YALNUENQHAQXEA-UHFFFAOYSA-N (en) |
| dbp:unii |
5 (xsd:integer) |
| dbp:verifiedfields |
changed (en) |
| dbp:verifiedrevid |
451563965 (xsd:integer) |
| dbp:watchedfields |
changed (en) |
| dbp:wikiPageUsesTemplate |
dbt:Cite_journal dbt:Cite_web dbt:Drugbox dbt:Refbegin dbt:Refend dbt:Reflist dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Stdinchicite dbt:HDAC_inhibitors |
| dcterms:subject |
dbc:Experimental_drugs dbc:Histone_deacetylase_inhibitors dbc:Orphan_drugs dbc:Diethylamino_compounds dbc:Hydroxamic_acids |
| gold:hypernym |
dbr:Inhibitor |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatAmines yago:WikicatCarbamates yago:WikicatNaphthalenes yago:Abstraction100002137 yago:Acid114607521 yago:AliphaticCompound114601294 yago:Amine114739004 yago:Carbamate114792281 yago:Chemical114806838 yago:Compound114818238 yago:Hydrocarbon114911057 yago:Material114580897 yago:Matter100020827 yago:MethaneSeries114951377 yago:Naphthalene114958564 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Relation100031921 yago:WikicatHydroxamicAcids dbo:Drug yago:Salt115010703 yago:Substance100019613 |
| rdfs:comment |
Givinostat ist ein in der klinischen Entwicklung befindlicher potenzieller Arzneistoff, der zur Behandlung der systemischen juvenilen idiopathischen Arthritis und der Polyzythämie eingesetzt werden soll. Arzneilich wird es als Hydrochlorid verwendet und befindet sich im Moment in Phase-2-Studien. (de) Givinostat ou gavinostat é um potêncial fármaco com propriedades anti-inflamatórias, antineoplásicas e antiangiogênese. Pertence a classe dos inibidores de HDAC (histone deacetylase). (pt) Givinostat (INN) or gavinostat (originally ITF2357) is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. It is a hydroxamate used in the form of its hydrochloride. Givinostat is in numerous phase II clinical trials (including for relapsed leukemias and myelomas), and has been granted orphan drug designation in the European Union for the treatment of systemic juvenile idiopathic arthritis, polycythaemia vera. and Duchenne muscular dystrophy. (en) |
| rdfs:label |
Givinostat (de) Givinostat (en) Givinostat (pt) |
| owl:sameAs |
freebase:Givinostat yago-res:Givinostat wikidata:Givinostat dbpedia-de:Givinostat dbpedia-fa:Givinostat dbpedia-pt:Givinostat dbpedia-sh:Givinostat dbpedia-sr:Givinostat dbpedia-tr:Givinostat https://global.dbpedia.org/id/3wyap |
| prov:wasDerivedFrom |
wikipedia-en:Givinostat?oldid=1033026498&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Givinostat_structure.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Givinostat |
| is dbo:wikiPageRedirects of |
dbr:Gavinostat dbr:ITF2357 |
| is dbo:wikiPageWikiLink of |
dbr:Histone_deacetylase_inhibitor dbr:List_of_drugs:_G dbr:Gavinostat dbr:ITF2357 |
| is foaf:primaryTopic of |
wikipedia-en:Givinostat |
